Immunovant, Inc.

NasdaqGS IMVT

Immunovant, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 2,238.96

Immunovant, Inc. Price to Sales Ratio (P/S) is 2,238.96 on January 14, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Immunovant, Inc. 52-week high Price to Sales Ratio (P/S) is 3,322.51 on September 06, 2024, which is 48.40% above the current Price to Sales Ratio (P/S).
Immunovant, Inc. 52-week low Price to Sales Ratio (P/S) is 2,226.24 on January 13, 2025, which is -0.57% below the current Price to Sales Ratio (P/S).
Immunovant, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 2,783.91.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: IMVT

Immunovant, Inc.

CEO	Dr. Peter Salzmann M.B.A., M.D.
IPO Date	June 21, 2019
Location	United States
Headquarters	320 West 37th Street
Employees	207
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Key trends

Past 5 years